Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients With Primary Biliary Cholangitis (PBC) With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA)
NCT07282353 is registered in ClinicalTrials.gov with Cascade Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients With Primary Biliary Cholangitis (PBC) With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA)
- Lead sponsor
- Cascade Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2025
- Completion date
- January 6, 2028
- Enrollment
- 135 (estimated)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
primary biliary cholangitis